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Abstract
Introduction: Advances in genomic analysis technologies have
led to the development of new diagnostic tests with clinical ap-
plication. Therefore, as in other diagnostic fields, awareness
of the methodological limitations of genetic investigation will
facilitate the application of the results.
Methods: 44 articles which studied the diagnostic accuracy
of genetic, molecular and proteomic tests, and published in
JAMA, Lancet, New England Journal of Medicine, Cancer Re-
search y Clinical Cancer Research from 2002 to June 2005
were analysed. 24 methodological criteria of the STARD guide
(Standards for Reporting of Diagnostic Accuracy) were applied.
Results: The mean number of methodological criteria satis-
fied was 9.8 (95%, CI 8.8-10.6), with the greatest deficiencies
observed in the aspects related to the description of patient
selection, 9 (20%), the treatment of indeterminate results, 5
(11%), and the determination of the technique’s reproducibil-
ity, 6 (13%). In contrast, a high frequency was observed in the
description of the reference standard, 39 (87%), and the method
used, 28 (62%).
Discussion: The articles evaluated fail to fulfil many of the
quality requirements laid out in the STARD proposal, with the
methodological quality being lower than in other diagnostic
fields. The aspects most in need of improvement are those
related to the description of patient selection and the deter-
mination of reproducibility. Research and progress in new ge-
netic-molecular technologies require improved fulfilment of the
epidemiological and clinical standards which are already ap-
plied by other diagnostic fields.
Key words: Genetic tests. Methodology. Sensitivity and spe-
cificity.
Resumen
Introducción: El avance en las tecnologías del análisis genómi-
co ha supuesto el desarrollo de nuevas pruebas diagnósticas
con potencial aplicación clínica. Así como ha sucedido en otros
campos del diagnóstico, conocer las limitaciones metodoló-
gicas de la investigación en genética facilitará la aplicación
de sus resultados.
Métodos: Se analizaron 44 artículos publicados en JAMA,
Lancet, New England Journal of Medicine, Cancer Research
y Clinical Cancer Research, de 2002 a junio de 2005, que es-
tudiaban la exactitud diagnóstica de pruebas genéticas, mo-
leculares y de proteómica. Se aplicaron 24 criterios metodológi-
cos de la guía STARD (Standards for Reporting of Diagnostic
Accuracy).
Resultados: La media de cumplimiento de los criterios apli-
cados fue de 9,8 (intervalo de confianza [IC] del 95%, 8,8-
10,6), y las mayores deficiencias se observaron en los aspectos
relacionados con la descripción de la selección de los pacientes
(9; 20%), el tratamiento de los resultados indeterminados (5;
11%) y la determinación de la reproducibilidad de la técnica
(6; 13%). En cambio, sí se observó una alta frecuencia en la
descripción del patrón de referencia (39; 87%) y del método
usado (28; 62%).
Discusión: Los artículos evaluados incumplen gran parte de
los requisitos de calidad recogidos en la propuesta STARD,
observándose una peor calidad metodológica que en otros
campos diagnósticos. Los aspectos que más necesitan mejo-
rar son los relacionados con la descripción de la selección de
los pacientes y la determinación de la reproducibilidad. La in-
vestigación y el avance en nuevas tecnologías genético-mo-
leculares requieren un mejor cumplimiento de los estándares
epidemiológicos y clínicos que ya se aplican a otros campos
diagnósticos.
Palabras clave: Pruebas genéticas. Metodología. Sensibili-
dad y especificidad.
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Introduction
The advances derived from the Human GenomeProject have led to the development of new kindsof diagnostic tests, genetic, molecular or prote-omic, which can be incorporated into clinical prac-
tice1-4. In Spain currently there are tests based on DNA
analysis for the diagnosis or prognosis of 214 genetic
369
Lumbreras B et al. Evaluation of the research methodology in genetic, molecular and proteomic tests
Gac Sanit. 2006;20(5):368-73
diseases5, and it is foreseen that in the coming years
this number of tests will multiply. This has given rise to
the elaboration of evaluation frameworks for the incor-
poration of new genetic tests to the list of services of
health systems6. The appearance of these new tests crea-
tes expectations, which often are not corroborated in 
clinical practice. This is due to the fact that sometimes
the results of basic research are publicised without awai-
ting confirmation from the results of clinical research;
at other times the clinical validation of the tests lacks
methodological rigour, precisely for their having been
developed in basic research environments without the
collaboration of investigators with experience in clinical
and epidemiological research. In any case the new ge-
netic-molecular technologies should not be introduced
for a specific clinical task (screening and genetic coun-
sel, diagnosis, risk evaluation, etc.), without prior exa-
mination of both their validity for this specific purpose
as well as their effects in health terms1.
A methodological deficit in the quality of research in
other diagnostic areas has been described7-12. In genetic-
molecular research, however, a single work analysed the
methodology of the studies published in four international
medical journals, showing that 63% of them fulfilled only
one of the required methodological criteria13.
In order to improve the articles on diagnostic research
and, as a result, the scientific quality of this research,
the STARD (Standards for Reporting of Diagnostic Ac-
curacy)14 was initiated, and its recommendations have
been incorporated by most of the scientific journals.
Moreover, Little and collaborators15 presented a list of
standards shared in part by STARD, but with some aimed
solely at research into markers based on genotypes,
which proposed to serve as a guide for authors as well
as editors and reviewers of genetics articles.
The works dealing with genetic-molecular tests have
a series of specificities, but these do not exclude the need
for fulfilment of the quality criteria that are demanded in
other diagnostic studies. Furthermore, the quality
achieved in the studies can differ depending on whether
the journal in which they are published belongs to the
clinical or diagnostic field. To determine whether genetic-
molecular research achieves the required quality, the stu-
dies on genetic-molecular diagnostic accuracy published
since the year 2002 in four very important international
clinical journals and in two journals of the American As-
sociation for Cancer Research (AACR), characterised
by including research on genetic-molecular tests, were
evaluated by applying the criteria of the STARD14 guide.
Methods
All original articles studying the diagnostic accura-
cy of genetic, molecular and proteomic tests from Jan-
uary 2002 to June 2005 in four international clinical jour-
nals (JAMA, British Medical Journal, Lancet and New
England Journal of Medicine) and 2 journals centred on
the field of cancer research belonging to the American
Association for Cancer Research (AACR) (Cancer Re-
search and Clinical Cancer Research) were reviewed.
Selection of articles
A search was conducted through the Medline com-
puterised bibliographic system using the search stra-
tegy employed by Devillé and collaborators16, combi-
ning the MESH terms «sensitivity and specificity» with
the words «false negative» and «accuracy». In order to
improve the sensitivity of the search it was widened with
the MESH term «area under the curve» and the words
«diagnostic odds ratio» and «likelihood ratio». After rea-
ding the summaries, all the articles in which human ge-
netic material was analysed at molecular level and all
proteomic studies were selected, without limiting the
search to any particular laboratory technique or clini-
cal condition.
Methodological standards
24 of the 25 criteria belonging to the STARD14 guide
were applied (the first standard of this guide was omit-
ted for being the criterion for inclusion in our study). The
given definitions were followed in all of them. Although
they can be consulted in detail in the reference publi-
cations, the following shows the methodological stan-
dards grouped into four blocks:
1. Introduction. Within the study aims, an estimate
of the diagnostic accuracy of a test should be included,
or the comparison of that accuracy among the tests or
participating groups (1).
2. Methods. The inclusion and exclusion criteria of
the participants in the study should appear (2) and the
place where the data or samples were gathered, as well
as specification of the reason for their choice (3). In the
case of it not being a consecutive sample of patients
then how they were assembled should be explained (4),
as well as the directionality of the study (5). On the test
being evaluated, the reference standard used should be
defined (6) and technical specifications given, which in-
clude how and when the measurements were made, for
both the diagnostic test and the reference standard (7).
The units and/or categories of the results of the diag-
nostic test and the reference standard should also be
described (8). Additionally, the number, training and ex-
perience of the people who have carried out and inter-
preted the tests and the reference standard should be
specified (9), and if the results have undergone blind
reviewing (10). The statistical methods used to calcu-
late and compare measurements of diagnostic accuracy
and to quantify the standard error should be described
(11), as too should the methods for calculating the re-
producibility of the tests (12).
3. Results. This section compiles characteristics of
when the study was carried out (13), the clinical and
demographic characteristics of the study population (14)
and the number of participants which satisfied the se-
lection criteria, and which then received or not the diag-
nostic test and/or the reference standard (this can be
illustrated with a flow diagram) (15). Also included is the
time interval between the application of the diagnostic
test, the reference standard and any other treatment ad-
ministered between these (16), the distribution of the
severity of the disease among the patients (17), a table
with the results of the diagnostic tests in comparison
with those obtained from the reference standard (18)
and the communication of any adverse effect produced
during the study (19). Lastly, the diagnostic accuracy
and the statistical precision should be estimated (20),
how indeterminate results have been treated (21), the
estimation of the variability of the diagnostic accuracy
for each subgroup of participants, researchers or cen-
tres (22), and the calculation of the reproducibility of the
technique (23).
4. Discussion. In this section it is important to com-
ment on the clinical applicability of the study findings (24).
Observer variability
In order to calculate the inter-observer variability in
the application of the criteria, 4 of the 44 works were
selected at random and reviewed independently by the
two observers. The degree of agreement reached be-
tween them was 86% (confidence interval [CI] 95%, 78-
92).
The creation and management of the data base and
the statistical analyses of the results were performed
with the SPSS statistical package (version 12 for Win-
dows Inc., Chicago, Illinois).
Results
In the study period 44 articles fulfilled the inclusion
criteria: 12 from Lancet, 6 from JAMA, 2 from New En-
gland Journal of Medicine, none from BMJ, 14 from Can-
cer Research and 10 from Clinical Cancer Research.
All of the articles reviewed evaluated tests centred
on the study of cancer, with prostate cancer, 10
(22.8%), and breast cancer, 7 (15.9%), being the most
frequent (table 1). Most of the diagnostic tests evalua-
ted, 37 (84%), were genetic, both microarray systems,
15 (41%), as well as genetic sequencing analysis, 12
(59%), and only 7 (16%) were proteomic. Of all the
works, 7 (16%), were prognostic in nature and most,
37 (84%), were diagnostic.
Mean fulfilment of the 24 methodological standards
applied was 9.8 (CI 95%, 8.8-10.6), and none of the 44
articles evaluated satisfied more than 18 criteria. No sta-
tistically significant differences were observed in the ful-
filment of the criteria before and after the year 2003 (pu-
blication of the STARD guide14).
Analysing the criteria individually, the greatest defi-
ciencies were found in the material and methods sec-
tion (table 2). Only 11 works (24%) specified the de-
termination of this diagnostic accuracy as being among
their objectives. Also low was the frequency with which
inclusion and exclusion criteria and the place of origin
of the subjects was specified (23%); the way in which
these were selected (20%), or whether this had been
planned before or after the performance of the diagnos-
tic test (27%). Regarding the performance of the test,
there was a low level of fulfilment in evaluators description,
1 work (2%), and whether the interpretation of the re-
sults was blinded, 12 articles (27%). The description of
the methods for studying the reproducibility of the test
was only communicated in 10 studies (23%) and the re-
sults obtained being shown in only 6 articles (13%).
With regard to the presentation of the results (table
3), most defined the clinical and demographic charac-
teristics of the study population, 34 (77%), but the rea-
sons for which some patients who fulfilled the inclusion
criteria but then did not continue in the study are hard-
ly given, 11 (25%). Only 12 studies (27%) investigated
whether the diagnostic sensitivity and specificity varied
according to relevant clinical subgroups. Communica-
tion and analysis of the indeterminate or imprecise re-
sults was very infrequent, 5 (11%).
If we compare the fulfilment of the criteria among
the clinical journals and those dedicated to cancer re-
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Table 1. Description of the diseases evaluated in the works on
investigation of genetic, molecular and proteomic tests
analysed in JAMA, New England Journal of Medicine, Lancet,
Cancer Research and Clinical Cancer Research (2002-2005)
Diseases n %
1. Prostate cancer 10 22.8
2. Breast cancer 7 15.9
3. Renal cancer 5 11.4
4. Ovary cancer 4 9.1
5. Hepatocellular carcinoma 4 9.1
6. Melanoma 4 9.1
7. Cancer of the colon 4 9.1
8. Lung cancer 2 4.5
9. Neuroblastoma 2 4.5
10. Bladder cancer 2 4.5
search (tables 2 and 3), it can be seen that statistical-
ly significant differences exist in certain standards. The
cancer-related journals fulfilled the definition of the tech-
nical specifications of the test better than the clinical pu-
blications, 21 (88%) and 7 (35%) respectively, and the
specification of the units employed in the test, 20 (83%)
compared to 7 (35%). They also expressed the corres-
pondence of the results of the reference standard with
the evaluated test more frequently, 22 (92%) compared
to 8 (40%), and the study of the variation of accuracy
according to relevant clinical subgroups, 10 (42%) com-
pared to 2 (10%). However, the clinical journals showed
greater fulfilment of the standards related to the blind
reviewing of the results compared to the cancer jour-
nals, 11 (55%) and 1 (4%) respectively, and to the pre-
sentation of the estimates of accuracy and their statis-
tical precision, 12 (60%) compared to 6 (25%).
Discussion
The articles on genetic-molecular diagnostic tests
published recently (2002-2005) in the best internatio-
nal journals of clinical medicine and in two important pu-
blications of cancer research, fail to satisfy most of the
quality requirements assembled in the STARD14 proposal.
This shortcoming could be a reflection of severe limi-
tations in the research methodology, or carelessness in
the preparation of the articles and their editorial process,
or both. If we compare with other diagnostic fields9-12, it
can be seen that genetic, proteomic and molecular stu-
dies show inferior methodological quality, while for ex-
ample in the laboratory field, and due fundamentally to
the efforts of different authors and editorial groups, there
has been a gradual improvement in their quality11.
The methodological quality found in both the clini-
cal journals as well as those dedicated to cancer re-
search is similar, although with some specificity. The most
analytical aspects, like the specification of the techni-
cal characteristics, are given more attention to in the can-
cer journals; while others more related to the way in
which to carry out the study, as for example the blind
reviewing of the results obtained, are better fulfilled in
the clinical journals.
The only antecedent in the field of genetic-molecu-
lar diagnosis of this kind of investigation was a review
carried out in 1995 on the same four clinical journals
as those analysed in this work13. Although the same
methodological criteria were not used, those employed
at that time are included in the STARD guide, and are
therefore comparable. As in this review, no work fulfilled
an acceptable number of methodological standards, the
calculation of the genetic test’s reproducibility was un-
usual and there was a general lack of blind reviewing
in the interpretation of the results. Hence it would ap-
pear that genetic-molecular diagnostic studies are
more impermeable to clinical-epidemiological advances.
Our intention of facilitating comparison with previous
works led us to the application of the same restrictive
selection criteria as employed previously7,9-12, and as a
result to a reduced sample of articles, a fact which li-
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Table 2. Fulfilment of the criteria relative to «Material and methods» for articles on investigation of genetic, molecular 
and proteomic tests in JAMA, New England Journal of Medicine, Lancet, Cancer Research and Clinical Cancer 
Research (2002-2005)
JAMA, Lancet and New England Cancer Research and
Criteria Journal of Medicine Clinical Cancer Research 
Total
(n = 20) (n = 24)
(n = 44)
1. Objectives 5 (25%) 6 (25%) 11 (24%)
Participants
2. Inclusion and exclusion criteria 8 (40%) 2 (8%) 10 (23%)
3. Assembling patients 18 (90%) 22 (92%) 40 (89%)
4. Sample selection 6 (30%) 3 (13%) 9 (20%)
5. Direction of the study 7 (35%) 5 (21%) 12 (27%)
Test
6. Description of the reference pattern 17 (85%) 22 (92%) 39 (87%)
7. Technical specifications: how and when 7 (35%)a 21 (88%)a 28 (62%)
8. Definition of the units 7 (35%) a 20 (83%)a 27 (61%)
9. People carrying out the test 1 (5%) 0 1 (2%)
10. Blind review 11 (55%)a 1 (4%)a 12 (27%)
Statistical methods
11. Statistical methods 9 (45%) 17 (71%) 26 (58%)
12. Reproducibility methods 4 (20%) 6 (25%) 10 (23%)
aStatistically significant differences (p < 0.05) between the two groups of journals calculated by the Fisher test.
mits the reach of the results. Nevertheless, by including
all the original articles which have been published on
the field of genetic and molecular diagnosis in the best
international journals of clinical medicine and in the two
publications of the American Association of Cancer Re-
search (for containing an important part of the works
published on the same matter), an adequate perspec-
tive of the quality of research and publication of this kind
of study is offered. The guide employed for the evalu-
ation of the articles (STARD) is very recent but has been
rapidly disseminated among most journals which pu-
blish diagnostic evaluations; in fact, two of them (JAMA
and Lancet) have included it among the rules for au-
thors17,18, although not so New England Journal of Medi-
cine or the two cancer journals. It could be argued that
there is little experience in its application, and it is true
that there may be doubts about the applicability of some
of its criteria due to the lack of precise indications. Ho-
wever, available experience shows that concordance on
its application is high among observers11,12, as it has been
too in the sample carried out in the present study. Moreo-
ver, many of the STARD criteria have already been ap-
plied in previous methodological guides7-12, which has
facilitated its use. Studies on diagnosis in genomics, pro-
teomics and related fields have some specificities in their
validation19 which the STARD guide does not include,
and although various initiatives have originated for the
elaboration of a set of guidelines suitable for the vali-
dation of these tests15, no definitive one has been drawn
up yet. This fact represents a limitation in that some in-
trinsic problems have not been evaluated, although they
are not exclusive to this field of research. One exam-
ple is «over-fitting», which occurs for example when a
proteomics profile is proposed and selected from a
broader group after countless discrimination trials,
which affects external validity. This problem is controlled
by determining the reproducibility of the discriminatory
pattern observed in samples independent of the origi-
nal. If the discrimination pattern cannot be reproduced
in other samples, the existence of «overfitting» is pro-
bable20.
Another limitation to bear in mind is the study pe-
riod, since the STARD criteria were first published early
in the year 200314, and this study recompiles articles from
2002 to 2005. Certainly it is early for the initiative to have
had effect, at least in the journals which have included
it in the instructions for their authors; and our study does
not have the statistical capacity to establish comparisons.
However, the fact that it was not published does not ex-
plain the low quality observed, as many of its criteria are
essential requirements in most observational studies al-
ready partially compiled —the most relevant ones— in
other guides and previous publications.
Not all the requirements have the same importance
in terms of their effects on the validity of the evaluated
studies. Bearing in mind the main characteristics that
a genetic test should possess for its correct use21, it is
important to underline the key aspects of validity which
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Table 3. Fulfilment of the criteria relative to the results and discussion of the articles on genetic, molecular 
and proteomic diagnostic tests in JAMA, New England Journal of Medicine, Lancet, Cancer Research and Clinical Cancer 
Research (2002-2005)
JAMA, Lancet and New England Cancer Research and
Criteria Journal of Medicine Clinical Cancer Research 
Total
(n = 20) (n = 24)
(n = 44)
Participants
13. Study dates 12 (60%) 6 (25%) 18 (41%)
14. Description of the subjects’ characteristics 15 (75%) 19 (79%) 34 (77%)
15. Presentation of the flow diagram 8 (40%) 3 (13%) 11 (25%)
Results of the test
16. Time between the test and the reference standard 4 (20%) 11 (46%) 15 (34%)
17. Distribution of the disease 16 (80%) 21 (86%) 37 (84%)
18. Results of the test and reference pattern 8 (40%)a 22 (92%)a 30 (68%)
19. Communication of adverse effects 0 0 0
Estimates
20. Presentation of the accuracy estimates and their statistical precision 12 (60%)a 6 (25%)a 18 (41%)
21. Communication of the indeterminate results 3 (215%) 2 (8%) 5 (11%)
22. Studies of the variation of the accuracy according to relevant clinical subgroups 2 (10%)a 10 (42%) a 12 (27%)
23. Determination of the reproducibility 3 (15%) 3 (13%) 6 (13%)
Discussion
24. Evaluation of the clinical applicability 9 (45%) 9 (42%) 18 (42%)
aStatistically significant differences (p < 0.05) calculated for χ2 between the two groups of journals calculated by the Fisher test.
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have shown themselves to be the most deficient. In first
place are the analytical characteristics of the test eva-
luated, as due to the current rapid development of ge-
netic tests for the same test there may be different tech-
niques and one should know which of them shows the
most acceptable values of diagnostic accuracy. Hence,
the scanty calculation of the technique’s reproducibili-
ty in the investigations evaluated is notable. In previous
reviews this concept was already considered essen-
tial7-12, and yet in the field of genetics or proteomics,
where the value of the determinations will also depend
on the capacity to give the same result when applied
to the same patients under the same conditions19, it has
been neglected all too often.
Secondly, another key methodological deficiency, and
one which limits the applicability of the results, is the
inadequate description of the inclusion and exclusion
criteria of the subjects participating in the study, these
barely appearing in less than half of the works evalua-
ted. This lack of information impedes detailed con-
sideration of the clinical applicability of the test evalua-
ted, which is an indispensable element in this kind of
investigation21.
To summarize, the future projection of the new ge-
netic-molecular technologies in the field of diagnosis and
precocious detection is very limited by the lack of rigour
in the research on these tests. These problems are at
the root of the reiterated false expectations which are
created around these diagnostic tests. If an effective in-
terdisciplinary relationship (basic, clinical, epidemio-
logical) which facilitated the rigorous development of
these genetic-molecular diagnostic tests existed then
a lot of unnecessary research would be avoided. Fur-
thermore, adherence to the methodological standards
would allow the genetic-molecular and proteomic tests
to become very useful tools in clinical and health ser-
vice research, especially in the field of cancer22.
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